Navigation Links
Chiltern Early Phase: Fully Integrated and Business Ready
Date:8/26/2008

LONDON, Aug. 27 /PRNewswire/ -- Following the successful acquisition of Drug Development Solutions ('DDS') in February, Chiltern, a leading contract research organization, announced today that it has fully integrated its two early Phase units into a single operation branded as Chiltern Early Phase.

Chiltern Early Phase is providing high quality early phase services for the pharmaceutical industry via its two well established units in Slough (just outside of London) and Dundee, Scotland. With a total of 72 high care beds, 42 of which are based at Ninewells Hospital in Dundee, Chiltern Early Phase can cover all therapeutic areas and all types of clinical pharmacology studies, with specialization in First Time in Man, drug photosensitivity, drug-drug interaction, Japanese bridging and vaccine studies.

Glenn Kerkhof, Chiltern's Chief Executive Officer said, "When we created Chiltern Early Phase, our vision was to develop a brand that would be synonymous with quality and service excellence. We now have the team, organization and facilities to deliver on this vision and provide a truly expert Early Phase service at reasonable cost."

Dr Brian Sanderson, Medical Director of Chiltern Early Phase commented, "I am delighted to see the integration completed so thoroughly and ahead of schedule. We are now looking to build on our units' long histories of good science and medicine, both in the areas where we have traditionally been strong but also in new areas of specialization such as diabetes and cardiovascular medicine. We are also looking forward to forging academic links to provide specialist studies involving new biomarkers."

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs over 1,250 people located in 23 offices throughout Europe, the Americas and Asia. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

For More Information Contact:

Catherine Lemercier

Chiltern International, Inc.

2111 Palomar Airport Road

Suite 200

Carlsbad

CA 92011

USA

Tel: 1 (760) 707 5025

Fax: 1 (760) 707 5022

Email: Catherine.Lemercier@chiltern.com

Richard Baptista

Chiltern International Ltd.

171 Bath Road

Slough

Berkshire

SL1 4AA

UNITED KINGDOM

Tel: 44 (0) 1753 512 000

Fax: 44 (0) 1753 511 116

Email: Richard.Baptista@chiltern.com


'/>"/>
SOURCE Chiltern
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pinnacle Biologics Announces Contract With Chiltern
2. Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT
3. Nano-sized electronic circuit promises bright view of early universe
4. New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
5. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
6. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
7. First semiconductor-based PET scanner demonstrates potential to aid in early diagnosis of disease
8. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
9. First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
10. Lilly Employees from Nearly 50 Nations Participate in Companys First-Ever Global Day of Service
11. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):